GILD

Gilead Sciences, Inc. Press Releases

$100.32
*  
0.02
0.02%
Get GILD Alerts
*Delayed - data as of Nov. 28, 2014  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry
11/26/2014 8:45:00 AM - PR Newswire


Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba
11/24/2014 8:45:00 AM - PR Newswire


Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power
11/20/2014 8:45:00 AM - PR Newswire


European Commission Grants Marketing Authorization for Gilead’s Harvoni®? (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
11/18/2014 10:07:00 AM - Business Wire


Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
11/18/2014 8:45:00 AM - PR Newswire


Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com
11/14/2014 8:45:00 AM - PR Newswire


Gilead Prices $4 Billion of Senior Unsecured Notes
11/12/2014 5:59:00 PM - Business Wire
▼-6.42 % Price Change since this news event. The Volume Ratio is 1.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
11/12/2014 8:45:00 AM - PR Newswire


Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
11/11/2014 8:00:00 AM - Business Wire
▼-6.77 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
11/11/2014 8:00:00 AM - Business Wire
▼-6.90 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Blue Line Protection Group Increases Its International Media Exposure With French Expose on Cannabis Industry
11/11/2014 8:00:00 AM - Market Wire


Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
11/10/2014 8:45:00 AM - PR Newswire


Surveyed U.S. Specialists Perceive Gilead's Harvoni, the First Single-Tablet Regimen for Hepatitis C Virus Infections, As Having Key Advantages Over Emerging Treatment Options
11/6/2014 11:00:00 AM - PR Newswire


Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
11/6/2014 8:30:00 AM - Business Wire
▼-6.14 % Price Change since this news event. The Volume Ratio is 0.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties
11/4/2014 8:45:00 AM - PR Newswire


Earnings Forecast Buzz for American Realty Capital Properties, Alibaba, Petroleo Brasileiro Petrobras SA, Gilead Sciences, RF Micro Devices, and GoPro
10/30/2014 8:45:00 AM - PR Newswire


Gilead Sciences Announces Third Quarter 2014 Financial Results
10/28/2014 4:05:00 PM - Business Wire
▼-10.23 % Price Change since this news event. The Volume Ratio is 2.19.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Earnings Forecast Research for DryShips, GoPro, Gilead Sciences, MannKind, GT Advanced Technologies, and Amazon
10/27/2014 8:45:00 AM - PR Newswire


Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014
10/21/2014 5:00:00 PM - Business Wire
▼-6.02 % Price Change since this news event. The Volume Ratio is 0.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
10/16/2014 1:30:00 PM - Business Wire
▲1.37 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
10/10/2014 1:54:00 PM - Business Wire
▼-4.89 % Price Change since this news event. The Volume Ratio is 14.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly
9/26/2014 7:18:00 AM - GlobeNewswire


European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults
9/26/2014 7:18:00 AM - Business Wire


Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies
9/24/2014 8:30:00 AM - Business Wire


Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection
9/24/2014 12:00:00 AM - Business Wire